Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

195
Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
195
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.7K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.7K
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

245
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
245
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

250
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
250
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026
Same author

Topography of Regional Cerebral GABA<sub>A</sub> Receptor Availability in Parkinson's Disease Patients With Freezing of Gait.

The European journal of neuroscience·2026
Same author

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
Same author

Excessive GABAergic activity in striatal and frontal cortical regions more than dopaminergic functions are related to daytime sleepiness in Parkinson's disease: An exploratory 11C-flumazenil PET study.

Geromedicine·2026
Same author

Cholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's disease.

Neural regeneration research·2026
Same author

Automated Imaging Differentiation for Dementia: Including Alzheimer Disease Dementia and Dementia with Lewy Bodies.

Neurology open access·2026

Related Experiment Video

Updated: May 7, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.2K

Dopamine overdose hypothesis: evidence and clinical implications.

David E Vaillancourt1, Daniel Schonfeld, Youngbin Kwak

  • 1Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida, USA; Department of Neurology, University of Florida, Gainesville, Florida, USA; Department of Biomedical Engineering, University of Florida, Gainesville, Florida, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|October 15, 2013
PubMed
Summary

Levodopa offers Parkinson's symptom relief but can impair cognitive functions. Individual factors like genetics and disease progression influence patient response to dopaminergic therapy.

Keywords:
dopaminedorsal striatumlearningprefrontal cortexventral striatum

More Related Videos

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

11.7K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.3K

Related Experiment Videos

Last Updated: May 7, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.2K
Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
11:26

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

11.7K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Science

Background:

  • Dopamine, identified as a neurotransmitter, plays a crucial role in motor control and cognitive functions.
  • Levodopa is a primary treatment for Parkinson's disease, alleviating motor symptoms.
  • Dopaminergic therapy's impact on cognition is complex, with potential for both improvement and impairment.

Purpose of the Study:

  • To review the evidence on how dopaminergic therapy affects cognitive functions, specifically reversal learning and motor sequence learning.
  • To explore the factors influencing individual responses to levodopa.
  • To understand the relationship between dopamine levels and cognitive performance.

Main Methods:

  • Review of accumulated scientific literature on dopaminergic therapy and cognitive tasks.
  • Analysis of multimodal neuroimaging studies.
  • Consideration of genetic polymorphisms and their role in dopaminergic function.

Main Results:

  • Dopaminergic medications can impair neural structures and associated behaviors.
  • The relationship between dopamine levels and performance follows a complex inverted-U shape.
  • Striatal denervation topography and individual genotype critically influence response to levodopa.
  • Dopaminergic therapy affects mesolimbic and prefrontal cortical functions in an inverted-U manner.

Conclusions:

  • Patient response to levodopa in cognitive tasks is highly individualized.
  • Factors such as disease progression, genetics, and drug dosage determine whether levodopa improves or worsens cognitive function.
  • Understanding these individual differences is crucial for optimizing Parkinson's disease treatment, especially in a technologically demanding world.